GSK's LAMA/LABA combo drug proves successful

The positive phase III clinical trial result of the combination LAMA/LABA medication manufactured by the GSK and Theravance pharma company that has been developed to treat COPD patients and the company plans to file for drug.

Fontana, CA (prHWY.com) August 7, 2012 - 7 August2012, USA California (Acedrugstore.com): An experimental and novel lung medication with is a combination drug of LAMA/LABA and produced by GlaxoSmithKline and Theravance pharmaceutical companies has been shown to provide positive results of its late stage phase III clinical trial studies in patients suffering from chronic obstructive pulmonary disease (COPD).
The drug manufacturer in an interview said that the company is planning to file this combination lung drug based on its phase III data to global drug regulators and agencies from this year end. Overall 1,500 COPD patients were enrolled in the study that took place for a period of around two-24 week clinical trial.

The combination drug that is code named GSK573719 contains umeclidinium bromide (UMEC), which is a long-acting muscarinic antagonist (LAMA) in conjugation with vilanterol (VI), which is a long-acting beta2 agonist (LABA). The combination drug has also outperformed its individual drug doses and should be administered with a novel inhaler of dry powder.
The 125/25mcg concentration of the drug combo LAMA/LABA has been found to provide a statistically significant result in the head-to-head investigative study conducted with Spiriva, an already approved lung drug that is currently in circulation in the market.
Darrell Baker, Head of the respiratory portfolio division of the GSK pharmaceutical company claimed that the current clinical studies along with the previous study work pertaining to the dose-range have built a confidence that the combo lung medication with its once a day prescription posses the potential to alleviate the complications of COPD patients.
He also added that this drug combination of LAMA/LABA is a breakthrough and significant clinical intervention of the company's huge respiratory drug collection.
The common side effects of the combination LAMA/LABA lung drug as per the data available from the overall clinical studies with respect to every drug combination including the placebo include back pain, headache, cough, common cold, sore throat and infections of upper respiratory tract.
For more: http://www.acedrugstore.com/kamagra-jelly.html
http://www.articlesbase.in/be-aware-of-those-allergic-foods/
Acedrugstore.com
4th lane, 278
Stockton, California states, USA

###

Tag Words: healthcare, health

Categories: Health

Press Release Contact
Acedrugstore.com
4th lane, 278
Stockton, California states, USA

Link To This Press Release:

URL HTML Code